HST-1011

N/A

Report date: 2023/04/12 14:55:32
NME

Base Information

Drug NameHST-1011
Drug Alias NameCBL B inhibitor (HotSpot Therapeutics)HST-1011HST1011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionE3 ubiquitin-protein ligase CBL-B inhibitorsProtein allosteric inhibitors
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHotSpot Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesHotSpot Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A